MedTrace Logo

Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)

NCT00095706 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2015-09-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and effectiveness of combined treatment with trastuzumab (Herceptin) and bevacizumab (anti-VEGF antibody) in patients with HER2-positive metastatic breast cancer.

Conditions

Interventions

DRUG

Bevacizumab (drug), Herceptin (drug)

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Translational Oncology Research International

    lead OTHER

Principal Investigators

  • Mark D Pegram, MD · University of California, Los Angeles

  • Fairooz Kabbinavar, MD · Chief Medical Officer, TORI

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Primary Completion
2007-04-30
Completion
2012-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00095706 on ClinicalTrials.gov